Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OPGEN INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)

07/13/2020 | 05:26pm EST

Item 1.01 Entry into a Material Definitive Agreement.

On July 9, 2020, OpGen, Inc. (the "Company"), as guarantor, Curetis GmbH ("Curetis"), a subsidiary of the Company, as borrower, Ares Genetics GmbH, a subsidiary of the Company ("Ares Genetics"), as guarantor, and the European Investment Bank, or, the Bank, entered into an Amendment and Restatement Agreement (the "Second Amendment and Restatement Agreement"), which provides for the further amendment of the Finance Contract, dated as of December 12, 2016, by and between the Borrower and the Bank, as amended and restated by the First Amendment and Restatement Agreement dated as of May 20, 2019 (the "Existing Finance Contract" and as amended pursuant to the Second Amendment and Restatement Agreement, the "Amended Finance Contract").



Existing Finance Contract


Curetis, as borrower, and the Bank, as lender, entered into the Existing Finance Contract, which originally provided for two term loan tranches in the aggregate principal amount of €25 million for the purpose of financing the development of novel test panels, as well as future panels on platforms such as the Unyvero Platform. The loan amount was split into two tranches, a first tranche of €10 million, which was drawn down in April 2017, and a second tranche of up to an additional €15 million, in respect of which a disbursement of €3 million was received on June 22, 2018 following the fulfillment of specified regulatory milestones. Subsequently, the disbursement of the balance of the second tranche, with an aggregate commitment of up to €12 million, was amended as follows: (i) a disbursement of up to €5 million became available subject to Curetis N.V., the former parent of Curetis, having raised cumulative new equity of at least €13.5 million and (ii) the remaining distribution amount of up to €7 million became available subject to Curetis having installed 350 Unyvero Analyzers globally as well as Curetis' consolidated revenues being at least €10 million over the 12 months preceding the request for the loan disbursement. In return for the Bank waiving certain conditions precedent to disbursing this aforementioned €5 million tranche mentioned in (i) above, the parties agreed on a 2.1% participation percentage interest. Upon maturity of this tranche, i.e. not before around mid-2024 (and no later than mid-2025), the Bank will be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis.

The Existing Finance Contract was backed by a guarantee from the European Fund for Strategic Investment. Receipt of the loans is limited to the purpose of financing the development of novel test panels, as well as future panels on platforms such as the Unyvero Platform (collectively, the "Financed Project"), provided that the loans made available by the Bank do not exceed 50% of the total cost of the Financed Project.

Each loan under the Existing Finance Contract matures on the fifth anniversary of the disbursement of that loan and is to be repaid as a single installment on its maturity date. Each loan bears interest in the form of (i) a cash interest element at a floating rate of EURIBOR plus a cash pay margin and (ii) a deferred interest element of a fixed interest rate to be paid on the maturity date of the relevant loan. As of June 30, 2020, €18.0 million plus deferred interest in the amount of approximately €3.4 million was outstanding under the Existing Finance Contract.

The Existing Finance Contract provided for certain compulsory prepayment events, such as if (i) the credit granted by the Bank exceeds 50% (fifty percent) of the total cost of the Financed Project by the Existing Finance Contract, (ii) the borrower, any guarantor or other member of the Curetis group of businesses (the "Curetis Group") voluntarily prepaid a part or the whole of any other financing arrangements, (iii) a change of control, defined as a person or group acting in concert gaining control of more than 50% of the equity (or gains the power to direct the management and policies) of the borrower, the guarantor or other member of the Curtis Group or any of the foregoing entities engaging in certain merger transactions or selling all or substantially all of its assets, occurs, (iv) the borrower's or a guarantor's ability to perform its obligations under this Existing Finance Contract or the guarantees would be materially impaired due to a change in or amendment to law, rule or regulation or (v) it becomes unlawful for the Bank to perform its obligations under the finance documents or to fund or maintain the loans.

The Existing Finance Contract contains undertakings on the part of the borrower to use the funds drawn down under the contract to finance the Financed Project and to maintain and insure the Financed Project, as well as certain restrictions, including restrictions on the borrower's ability to dispose of assets, engage in hedging activities, violate applicable law, dispose of the shares of its material subsidiaries, engage in certain acquisitions, grant guarantees and security other than certain types of permitted guarantees and security, and incur additional financial indebtedness other than certain types of permitted indebtedness. The borrower is required to repay the loan together with accrued interest and any deferred interest upon demand by the Bank in the event of default, including payment defaults subject to a three-day grace period, certain insolvency or bankruptcy events, or the inability of the borrower or guarantor to fulfill its other obligations under the Existing Finance Contract or the guarantees.

Second Amendment and Restatement Agreement

The Second Amendment and Restatement Agreement (i) amends certain provisions the Existing Finance Contract to reflect the changes made as a result of the Company's acquisition of the Borrower, including the addition of the Company and Ares Genetics as guarantors, and (ii) provides for an additional €5 million in available borrowings, payable upon satisfaction of certain conditions, to fund certain research and development costs in relation to the Borrower's project to develop diagnostic solutions for COVID-19. The conditions to the disbursement of the additional €5 million in available borrowings include, among others things, the entry into a security agreement by Ares Genetics pursuant to which Ares Genetics will grant the Bank a security interest in certain patents.

Pursuant to the terms of the Second Amendment and Restatement Agreement, each of the Company and Ares Genetics also entered into Guarantee and Indemnity Agreements, each dated July 9, 2020, with the Bank, pursuant to which the Company and Ares Genetics guaranteed the obligations and liabilities of the Borrower under the Amended Finance Contract. Under the terms of the Guarantee Agreements, the Company and Ares Genetics provide customary representations and warranties and are subject to customary affirmative and restrictive covenants.

Copies of the Second Amendment and Restatement Agreement, which includes the Amended Finance Contract, are attached as Exhibits 10.1 and 10.2 hereto, respectively, and are incorporated herein by reference. Copies of the Guarantee . . .

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.


Item 8.01 Other Events.


On July 9, 2020, the Company issued a press release announcing the entry into the Second Amendment and Restatement Agreement with the Bank as described above in Item 1.01 and Item 2.03 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.     Document
10.1      Amendment and Restatement Agreement, dated as of July 9, 2020, by and
        among Curetis GmbH, as borrower, the Company, as guarantor, Ares Genetics
        GmbH, as guarantor, and European Investment Bank
10.2      Finance Contract, as amended and restated pursuant to the First
        Amendment and Restatement Agreement dated May 20, 2019 and the Second
        Amendment and Restatement Agreement dated as of July 9, 2020, by and
        between the European Investment Bank and Curetis GmbH*
10.3      Guarantee and Indemnity Agreement, dated as of July 9, 2020, by and
        between European Investment Bank and the Company
10.4      Guarantee and Indemnity Agreement, dated as of July 9, 2020, by and
        between European Investment Bank and Ares Genetics
99.1      Press Release issued by OpGen, Inc. dated July 9, 2020

* Confidential treatment has been requested for certain portions of this agreement. The unredacted document will be provided supplementally to the Securities and Exchange Commission upon request.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
12/01OPGEN : Corporate Presentation (PDF)
PU
12/01OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Pres..
GL
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -26,4 M - -
Net Debt 2020 14,6 M - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 44,3 M 44,3 M -
EV / Sales 2020 14,3x
EV / Sales 2021 7,36x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,97 $
Spread / Highest target 187%
Spread / Average Target 170%
Spread / Lowest Target 154%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.76.11%44
MODERNA, INC.705.88%56 587
LONZA GROUP AG56.34%45 782
CELLTRION, INC.93.92%42 101
IQVIA HOLDINGS INC.8.49%32 601
SEAGEN INC.57.68%31 921